302 related articles for article (PubMed ID: 28429242)
1. Genetics of Dyslipidemia and Ischemic Heart Disease.
Sharma K; Baliga RR
Curr Cardiol Rep; 2017 May; 19(5):46. PubMed ID: 28429242
[TBL] [Abstract][Full Text] [Related]
2. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
4. Role of DNA copy number variation in dyslipidemias.
Iacocca MA; Hegele RA
Curr Opin Lipidol; 2018 Apr; 29(2):125-132. PubMed ID: 29303791
[TBL] [Abstract][Full Text] [Related]
5. Update on the molecular biology of dyslipidemias.
Ramasamy I
Clin Chim Acta; 2016 Feb; 454():143-85. PubMed ID: 26546829
[TBL] [Abstract][Full Text] [Related]
6. Understanding PCSK9 and anti-PCSK9 therapies.
McKenney JM
J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Momtazi AA; Banach M; Pirro M; Stein EA; Sahebkar A
Clin Rev Allergy Immunol; 2018 Apr; 54(2):224-233. PubMed ID: 28534160
[TBL] [Abstract][Full Text] [Related]
9. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
10. Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands.
Zuurbier LC; Defesche JC; Wiegman A
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440342
[TBL] [Abstract][Full Text] [Related]
11. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
13. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
Ferri N; Ruscica M
Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
[TBL] [Abstract][Full Text] [Related]
16. [Congenital disorders of lipoprotein metabolism].
März W; Grammer TB; Delgado G; Kleber ME
Herz; 2017 Aug; 42(5):449-458. PubMed ID: 28555288
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
Page MM; Stefanutti C; Sniderman A; Watts GF
Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
20. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
Ooi EM; Barrett PH; Watts GF
Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
